about
Nonselective coupling of the human mu-opioid receptor to multiple inhibitory G-protein isoformsMolecular and functional dissection of the H-2Db-restricted subdominant cytotoxic T-cell response to lymphocytic choriomeningitis virus.Melanoma chemotherapy leads to the selection of ABCB5-expressing cellsConsequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2'-deoxycytidine in human leukemic KG1 cellsCombined analysis of DNA methylation and cell cycle in cancer cells.In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth.The innate immune system recognizes and regulates major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells.Interactions between CD8alphabeta and the TCRalphabeta/CD3-receptor complex.Structural and functional identification of major histocompatibility complex class I-restricted self-peptides as naturally occurring molecular mimics of viral antigens. Possible role in CD8+ T cell-mediated, virus-induced autoimmune disease.Agonist-induced signaling and trafficking of the mu-opioid receptor: role of serine and threonine residues in the third cytoplasmic loop and C-terminal domain.Demethylation by low-dose 5-aza-2'-deoxycytidine impairs 3D melanoma invasion partially through miR-199a-3p expression revealing the role of this miR in melanomaSphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in MelanomaGenetically encoded and post-translationally modified forms of a major histocompatibility complex class I-restricted antigen bearing a glycosylation motif are independently processed and co-presented to cytotoxic T lymphocytesPleiotropic effects of post-translational modifications on the fate of viral glycopeptides as cytotoxic T cell epitopes
P50
Q28640362-075B620C-4628-4D84-9737-04035B11B9FFQ33850918-A4B57592-9E15-4182-BA18-4FA01F6AADA9Q34295399-4590BD04-14E1-42E2-B6CE-2D6E067A5942Q36020996-7E98526F-37ED-4C3B-907B-B2764C36BF19Q38926364-DDC25C43-DF5B-46BD-9A87-0AA570A4A77AQ39781532-F94C95C1-8629-430E-8E7B-E2FB45B19EEAQ39941375-9FE18DE7-F7AB-40B2-8A78-2EEA9F663ABCQ40242085-7BA30592-9A6A-43CD-A632-A8F2C2DDE87FQ40817198-FA2622A8-1766-47D0-8BAD-760D97C54568Q44347136-C5BF6074-6CFF-4025-8F20-6335B138D394Q61447666-A8B71DEA-E20C-4657-805B-BEB2C600EA6CQ64079022-0FB4978B-77F9-4927-B78E-6294467E860CQ73263441-A300E310-5552-448F-AA04-557A69A68243Q74293110-E3AE8127-0638-499F-8E02-ED3CC1090231
P50
description
researcher
@en
name
J Riond
@en
J Riond
@nl
type
label
J Riond
@en
J Riond
@nl
prefLabel
J Riond
@en
J Riond
@nl
P106
P31
P496
0000-0002-6281-2376